AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteVoruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PageVoruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PageVS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
More Information Supplier PageVS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
More Information Supplier PageVS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
More Information Supplier PageVS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
More Information Supplier PageVTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.
More Information Supplier PageVTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.
More Information Supplier PageVTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.
More Information Supplier PageVTP-27999 HCl is a potent inhibitor of renin with IC50 value of 0.3 nM for human renin.
More Information Supplier PageVTP-27999 HCl is a potent inhibitor of renin with IC50 value of 0.3 nM for human renin.
More Information Supplier PageVTX-2337 is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities.
More Information Supplier PageVTX-2337 is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities.
More Information Supplier PageVTX-2337 is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities.
More Information Supplier PageVTX-2337 is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities.
More Information Supplier PageVU 0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax.
More Information Supplier PageVU 0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax.
More Information Supplier PageVU 0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax.
More Information Supplier PageVU 0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax.
More Information Supplier PageVU 0357121 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGlu5) with EC50 = 33 nM, 92% Glumax.
More Information Supplier PageVU 0361737 is a selective positive allosteric modulator at mGluR-4 (EC50 values are 240 and 110 nM at human and rat receptors respectively).
More Information Supplier PageVU 0361737 is a selective positive allosteric modulator at mGluR-4 (EC50 values are 240 and 110 nM at human and rat receptors respectively).
More Information Supplier PageVU 0361737 is a selective positive allosteric modulator at mGluR-4 (EC50 values are 240 and 110 nM at human and rat receptors respectively).
More Information Supplier PageVU 0361737 is a selective positive allosteric modulator at mGluR-4 (EC50 values are 240 and 110 nM at human and rat receptors respectively).
More Information Supplier PageVU 0364439 is a positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).
More Information Supplier PageVU 0364439 is a positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).
More Information Supplier PageVU 0364439 is a positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).
More Information Supplier PageVU 0364439 is a positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).
More Information Supplier PageVU 0364439 is a positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).
More Information Supplier PageVX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.
More Information Supplier PageVX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.
More Information Supplier PageVX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.
More Information Supplier PageVX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.
More Information Supplier PageVX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.
More Information Supplier PageVX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.
More Information Supplier PageVX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.
More Information Supplier PageVX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.
More Information Supplier PageVX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.
More Information Supplier PageVX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.
More Information Supplier PageVX-680 is a potent and selective small-molecule inhibitor of the Aurora kinases.
More Information Supplier PageVX-680 is a potent and selective small-molecule inhibitor of the Aurora kinases.
More Information Supplier PageVX-680 is a potent and selective small-molecule inhibitor of the Aurora kinases.
More Information Supplier PageVX-680 is a potent and selective small-molecule inhibitor of the Aurora kinases.
More Information Supplier PageVX-680 is a potent and selective small-molecule inhibitor of the Aurora kinases.
More Information Supplier PageVX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier Page
